8-K: Telomir Submits IND for Telomir-1 in Advanced TNBC

Telomir Pharmaceuticals announced the submission of an Investigational New Drug application to the FDA for Telomir-1 (Telomir-Zn) to treat advanced and metastatic Triple-Negative Breast Cancer.

Summary

• Telomir Pharmaceuticals, Inc. submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Telomir-1 (Telomir-Zn).
• The IND is for the treatment of advanced and metastatic Triple-Negative Breast Cancer (TNBC).
• Telomir-1 is described as a first-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways.
• The submission includes data from completed IND-enabling pharmacology, toxicology, and manufacturing studies.
• Subject to FDA clearance, the company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-1 as an oral monotherapy in patients with advanced or metastatic TNBC.
• The Phase 1 portion will use a 3+3 dose-escalation design to assess safety, tolerability, dose-limiting toxicities, and determine a recommended Phase 2 dose.
• The Phase 2 portion will evaluate preliminary antitumor activity using a Simon two-stage design, with objective response rate as the primary endpoint.
• Preclinical studies demonstrated Telomir-Zn's ability to reduce tumor growth and metastatic dissemination in TNBC models, and induce iron-dependent tumor cell mortality across several human TNBC cell lines.
• IND-enabling Good Laboratory Practice (GLP) safety studies showed no treatment-related adverse or dose-limiting toxicities.
• The company is continuing to evaluate Telomir-Zn in additional preclinical TNBC models and advancing biomarker strategies.
• Scientific manuscripts have been submitted to peer-reviewed journals, and data presentations are planned for scientific conferences, including the AACR Annual Meeting 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, marking a crucial step forward in the clinical development of Telomir-1, though significant clinical hurdles remain as it progresses from preclinical to human trials.

Positives

• Submission of the Investigational New Drug (IND) application to the FDA marks a significant step towards clinical trials for Telomir-1.
• Preclinical studies demonstrated promising efficacy, including reduction in tumor growth and metastatic dissemination in Triple-Negative Breast Cancer (TNBC) models.
• Telomir-1 exhibited iron-dependent tumor cell mortality across several human TNBC cell lines.
• IND-enabling GLP safety studies showed a favorable safety profile with no treatment-related adverse or dose-limiting toxicities observed.
• The drug's mechanism as a first-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways offers a novel approach to TNBC treatment.

Risks

• Initiation of the planned Phase 1/2 clinical trial is subject to clearance of the IND by the FDA, which is not guaranteed.

Future Outlook

Subject to FDA clearance of the IND, Telomir Pharmaceuticals plans to initiate a Phase 1/2 clinical trial for Telomir-1 in advanced and metastatic TNBC. The company will continue preclinical evaluation of Telomir-Zn, advance biomarker strategies, and present data at scientific conferences, including the AACR Annual Meeting 2026.

Management Comments

• The company reported that, in preclinical studies, Telomir-Zn demonstrated a reduction in tumor growth and metastatic dissemination in TNBC models, as well as iron-dependent tumor cell mortality across several human TNBC cell lines.
• The company previously reported results from IND-enabling Good Laboratory Practice (GLP) safety studies in which no treatment-related adverse or dose-limiting toxicities were observed.
• The company stated that it is continuing to evaluate Telomir-Zn in additional preclinical TNBC models and is advancing biomarker strategies to support clinical development.
• The company indicated that it has submitted scientific manuscripts to peer-reviewed journals and plans to present data at scientific conferences, including the AACR Annual Meeting 2026.

Industry Context

StockSavvy.ai notes that Triple-Negative Breast Cancer (TNBC) is a particularly aggressive and challenging form of breast cancer with limited targeted treatment options. The development of novel therapies like Telomir-1, which targets iron-dependent epigenetic pathways, could represent a significant advancement in addressing this unmet medical need within the oncology landscape.

Stakeholder Impact

• Shareholders: Potential positive impact due to advancement of the lead drug candidate into clinical development, subject to FDA clearance.
• Patients: Potential future treatment option for advanced and metastatic Triple-Negative Breast Cancer, a disease with high unmet medical need.
• Scientific Community: Contribution of new preclinical data and planned presentations at conferences like AACR Annual Meeting 2026.

Next Steps

• FDA clearance of the Investigational New Drug (IND) application.
• Initiation of a Phase 1/2 clinical trial for Telomir-1 in advanced or metastatic TNBC.
• Continued evaluation of Telomir-Zn in additional preclinical TNBC models.
• Advancing biomarker strategies to support clinical development.
• Presentation of data at scientific conferences, including the AACR Annual Meeting 2026.
• Submission of scientific manuscripts to peer-reviewed journals.

Key Dates

Recommendation

The IND submission for Telomir-1 is a positive and expected step for Telomir Pharmaceuticals, demonstrating progress in its pipeline. However, the drug is still in the very early stages of clinical development, and the success of future Phase 1/2 clinical trials remains uncertain, warranting a 'hold' position for now as investors await further clinical data.

Keywords

Telomir Pharmaceuticals, Telomir-1, Telomir-Zn, IND, FDA, Triple-Negative Breast Cancer, TNBC, Oncology, Epigenetic Therapy, Clinical Trial, Phase 1/2, Drug Development